November 1, 2018 05:34 AM EDT
R&D

As ri­vals press in, Stan­ford spin­out Forty Sev­en bur­nish­es its prospects from an im­pres­sive PhIb

John Carroll

Editor & Founder

Irv Weiss­man’s an­ti-CD47 can­cer drug is in the spot­light to­day with ear­ly but re­mark­able da­ta pub­lished in the NE­JM to un­der­score its po­ten­tial as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times